Takeda Pharmaceutical Ltd ADR
1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KUTOKYO M0 103-8668 JPN
P: 813-3278-2306
F: +81 332782268
http://www.takeda.com
Profile
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.
Key Executives
Name | Title |
---|---|
Christophe Weber | CEO/Director/Other Corporate Officer/President |
Andrew S. Plump | Director/President, Divisional |
Marcello Agosti | Other Corporate Officer |
Teresa Marie Bitetti | President, Divisional |
Milano Furuta | CFO/Director |
Julie Kim | Other Corporate Officer/President, Geographical |
Mwana Lugogo | Chief Compliance Officer/Other Executive Officer |
Yoshihiro Nakagawa | General Counsel |
Giles Platford | President, Divisional |
Ramona Sequeira | President, Divisional |
Thomas Wozniewski | Other Corporate Officer |
Takako Ohyabu | Other Executive Officer |
Lauren Duprey | Other Executive Officer |
Gabriele Ricci | Chief Technology Officer/Other Executive Officer |
Akiko Amakawa | Other Corporate Officer/Other Executive Officer |
Asuka Miyabashira | President, Geographical |
Elaine Shannon | Other Corporate Officer |